Pfizer Oncologic Sutent Will Have Dosing, Slight Price Advantage Over Nexavar
Executive Summary
Pfizer's newly approved oncologic Sutent will have a dosing advantage and will be priced at a slight discount compared to Bayer/Onyx' Nexavar
You may also be interested in...
Torisel’s Positive Effect on Overall Survival Expected To Drive Sales
Wyeth is projecting that Torisel will capture a 25 percent share of the global renal cell carcinoma market within three years following its July launch
Torisel’s Positive Effect on Overall Survival Expected To Drive Sales
Wyeth is projecting that Torisel will capture a 25 percent share of the global renal cell carcinoma market within three years following its July launch
NME Slump Continues: FDA Clears 18 Novel Drugs In 2006, Same As 2005
FDA's final approval tally of new molecular entities in 2006 is almost a 25-year low, despite early signs that the agency was on pace to best last year's final count of NME approvals